AR070119A1 - Derivados de insulina con perfil tiempo / accion extremadamente retardado - Google Patents
Derivados de insulina con perfil tiempo / accion extremadamente retardadoInfo
- Publication number
- AR070119A1 AR070119A1 ARP090100036A ARP090100036A AR070119A1 AR 070119 A1 AR070119 A1 AR 070119A1 AR P090100036 A ARP090100036 A AR P090100036A AR P090100036 A ARP090100036 A AR P090100036A AR 070119 A1 AR070119 A1 AR 070119A1
- Authority
- AR
- Argentina
- Prior art keywords
- corresponds
- glu
- asp
- chemical bond
- lys
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Análogos de insulina con perfil basal de tiempo/accion, que se caracterizan por la adicion y/o sustitucion de residuos aminoácidos cargados negativa y positivamente, y una amidacion del grupo carboxi C-terminal de la cadena B e histidina en la posicion 8 de la cadena A de la insulina, a su preparacion y uso. Reivindicacion 1: Un análogo de insulina de la formula (1) en que A-1 corresponde a Lys, Arg o un grupo amino; A0 corresponde a Lys, Argo un enlace químico; A1 corresponde a Arg o Gly; A5 corresponde a Asp, Glu o Gln; A15 corresponde a Asp, Glu o Gln; A18 corresponde a Asp, Glu o Asn; A21 corresponde a Ala, Ser, Thr o Gly; B-1 corresponde a Asp, Glu o un grupo amino; B0 corresponde a Asp, Glu o un enlace químico; B1 corresponde a Asp, Glu, Phe o un enlace químico; B3 corresponde a Asp, Glu o Asn; B4 corresponde a Asp, Glu o GIn; B29 corresponde a Arg, Lys o un aminoácido seleccionado del grupo que comprende los aminoácidos Phe, Ala, Thr, Ser, Val, Leu, Glu o Asp, o un enlace químico; B30 corresponde a Thr o un enlace químico; B31 corresponde a Arg, Lys o un enlace químico; B32 corresponde a Arg-amida o Lys-amida, en que no más de un residuo aminoácido del grupo que comprende A5, A15, A18, B-1, B0, B1, B2, B3 y B4 corresponde, simultánea e independientemente uno de otro, a Asp o Glu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008003566A DE102008003566A1 (de) | 2008-01-09 | 2008-01-09 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| DE200810025007 DE102008025007A1 (de) | 2008-05-24 | 2008-05-24 | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070119A1 true AR070119A1 (es) | 2010-03-17 |
Family
ID=40473425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100036A AR070119A1 (es) | 2008-01-09 | 2009-01-07 | Derivados de insulina con perfil tiempo / accion extremadamente retardado |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8633156B2 (es) |
| EP (1) | EP2229406B1 (es) |
| JP (1) | JP5695909B2 (es) |
| KR (1) | KR20100111683A (es) |
| CN (1) | CN101970476B (es) |
| AR (1) | AR070119A1 (es) |
| AU (1) | AU2009203810B2 (es) |
| BR (1) | BRPI0907119A2 (es) |
| CA (1) | CA2711752A1 (es) |
| CL (1) | CL2009000018A1 (es) |
| CO (1) | CO6290770A2 (es) |
| IL (1) | IL206843A0 (es) |
| MA (1) | MA31997B1 (es) |
| NZ (1) | NZ586589A (es) |
| PA (1) | PA8811501A1 (es) |
| PE (1) | PE20091305A1 (es) |
| TW (1) | TWI433681B (es) |
| UY (1) | UY31597A1 (es) |
| WO (1) | WO2009087082A2 (es) |
| ZA (1) | ZA201003927B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005046113A1 (de) * | 2005-09-27 | 2007-03-29 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen |
| DK2229407T3 (en) | 2008-01-09 | 2017-02-27 | Sanofi Aventis Deutschland | NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE |
| CN103736082A (zh) | 2008-10-17 | 2014-04-23 | 赛诺菲-安万特德国有限公司 | 胰岛素和glp-1激动剂的组合 |
| EA020596B1 (ru) | 2008-12-15 | 2014-12-30 | Зилэнд Фарма А/С | Аналоги глюкагона |
| US8642541B2 (en) | 2008-12-15 | 2014-02-04 | Zealand Pharma A/S | Glucagon analogues |
| US8685919B2 (en) | 2008-12-15 | 2014-04-01 | Zealand Pharma A/S | Glucagon analogues |
| AU2008365556A1 (en) | 2008-12-15 | 2011-07-21 | Zealand Pharma A/S | Glucagon analogues |
| DK2454282T3 (en) | 2009-07-13 | 2015-05-04 | Zealand Pharma As | acetylated glucagonanaloger |
| CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
| AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| KR20130086343A (ko) | 2010-06-24 | 2013-08-01 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| EP3124041A1 (en) | 2010-06-24 | 2017-02-01 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
| US20120283169A1 (en) | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| KR20140043709A (ko) | 2011-01-20 | 2014-04-10 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체와 인슐린 유사체의 조합 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| ES2550357T3 (es) | 2011-08-29 | 2015-11-06 | Sanofi-Aventis Deutschland Gmbh | Combinación farmacéutica para su uso en el control glucémico en pacientes de diabetes de tipo 2 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| CA2878991C (en) | 2012-07-23 | 2021-12-07 | Zealand Pharma A/S | Glucagon analogues |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| PT3057984T (pt) | 2013-10-17 | 2018-10-24 | Boehringer Ingelheim Int | Análogos de glucagon acilados |
| JP2017503474A (ja) | 2013-11-06 | 2017-02-02 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物 |
| MX2016005556A (es) | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| KR20160104726A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형 |
| RU2016132342A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных |
| JP6735674B2 (ja) | 2014-01-09 | 2020-08-05 | サノフイＳａｎｏｆｉ | インスリンアスパルトの安定化された医薬製剤 |
| CR20160376A (es) * | 2014-01-20 | 2016-10-07 | Hanmi Pharm Ind Co Ltd | Insulina de acción prolongada y uso de la misma |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| US10253078B2 (en) | 2014-10-29 | 2019-04-09 | Zealand Pharma A/S | GIP agonist compounds and methods |
| KR102578030B1 (ko) | 2014-12-12 | 2023-09-14 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린 글라진／릭시세나티드 고정비 제형 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| DK3283507T3 (da) | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| KR102698929B1 (ko) * | 2016-09-23 | 2024-08-27 | 한미약품 주식회사 | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 |
| AR111341A1 (es) | 2017-03-23 | 2019-07-03 | Hanmi Pharm Ind Co Ltd | Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo |
| CN110615836B (zh) * | 2018-06-20 | 2022-09-13 | 鲁南制药集团股份有限公司 | 一种利拉鲁肽的固相合成方法 |
| CN115702880B (zh) * | 2021-08-12 | 2023-11-03 | 山东新时代药业有限公司 | 一种重组甘精胰岛素注射液及其制备工艺 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5008241A (en) * | 1985-03-12 | 1991-04-16 | Novo Nordisk A/S | Novel insulin peptides |
| DK113585D0 (da) | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
| DK347086D0 (da) * | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
| FI884914A0 (fi) | 1987-02-25 | 1988-10-24 | Novo Industri As | Nya insulinderivat. |
| DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
| DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| US5225323A (en) * | 1988-11-21 | 1993-07-06 | Baylor College Of Medicine | Human high-affinity neurotransmitter uptake system |
| DK134189D0 (da) * | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
| IL95495A (en) | 1989-08-29 | 1996-10-16 | Hoechst Ag | Fusion proteins their preparation and use |
| DK10191D0 (da) | 1991-01-22 | 1991-01-22 | Novo Nordisk As | Hidtil ukendte peptider |
| DE4405388A1 (de) | 1994-02-19 | 1995-08-24 | Hoechst Ag | Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen |
| WO1996034882A1 (en) | 1995-05-05 | 1996-11-07 | Eli Lilly And Company | Single chain insulin with high bioactivity |
| UA72181C2 (uk) | 1996-08-30 | 2005-02-15 | Ново Нордіск А/С | Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| US6444641B1 (en) * | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| PE123799A1 (es) | 1997-10-24 | 1999-12-13 | Lilly Co Eli | Composiciones insolubles de insulina |
| AU3185799A (en) | 1998-03-12 | 1999-09-27 | Biopore, Inc. | Enhancement of the pro-fertility action of a molecule involved in sperm-egg binding |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| DE19947456A1 (de) | 1999-10-02 | 2001-04-05 | Aventis Pharma Gmbh | C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| DE10108211A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen |
| DE10108212A1 (de) | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
| ES2333942T3 (es) * | 2001-04-02 | 2010-03-03 | Novo Nordisk A/S | Precursores de insulina y proceso para su preparacion. |
| CZ2004710A3 (cs) * | 2001-12-20 | 2005-02-16 | Eli Lilly And Company | Inzulínová sloučenina s protrahovaným účinkem |
| US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| DK1525219T3 (da) | 2002-07-04 | 2009-09-07 | Zealand Pharma As | GLP-1 og fremgangsm der til behandling af diabetes |
| AU2003268621B2 (en) * | 2002-10-02 | 2009-01-15 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
| WO2004096854A2 (en) | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| CN1780854A (zh) * | 2003-04-29 | 2006-05-31 | 伊莱利利公司 | 具有延长时间作用的胰岛素类似物 |
| BRPI0512396A (pt) * | 2004-07-21 | 2008-03-11 | Ambrx Inc | polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente |
| EP1791554A2 (en) | 2004-09-17 | 2007-06-06 | Novo Nordisk A/S | Pharmaceutical compositions containing insulin and insulinotropic peptide |
| DE102004058306A1 (de) | 2004-12-01 | 2006-07-27 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden |
| AU2006291780B2 (en) | 2005-09-14 | 2011-12-08 | F. Hoffmann-La Roche Ag | Cleavage of precursors of insulins by a variant of trypsin |
| US8343914B2 (en) * | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
| US9445113B2 (en) | 2006-01-10 | 2016-09-13 | Thomson Licensing | Methods and apparatus for parallel implementations of 4:4:4 coding |
| DK2229407T3 (en) | 2008-01-09 | 2017-02-27 | Sanofi Aventis Deutschland | NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / EFFECTS PROFILE |
-
2009
- 2009-01-06 CA CA2711752A patent/CA2711752A1/en not_active Abandoned
- 2009-01-06 KR KR1020107014964A patent/KR20100111683A/ko not_active Ceased
- 2009-01-06 NZ NZ586589A patent/NZ586589A/en not_active IP Right Cessation
- 2009-01-06 CN CN200980101942.6A patent/CN101970476B/zh not_active Expired - Fee Related
- 2009-01-06 AU AU2009203810A patent/AU2009203810B2/en not_active Ceased
- 2009-01-06 EP EP09700949.2A patent/EP2229406B1/de active Active
- 2009-01-06 BR BRPI0907119-9A patent/BRPI0907119A2/pt not_active Application Discontinuation
- 2009-01-06 WO PCT/EP2009/000018 patent/WO2009087082A2/de not_active Ceased
- 2009-01-06 JP JP2010541744A patent/JP5695909B2/ja not_active Expired - Fee Related
- 2009-01-07 PE PE2009000010A patent/PE20091305A1/es not_active Application Discontinuation
- 2009-01-07 PA PA20098811501A patent/PA8811501A1/es unknown
- 2009-01-07 TW TW098100283A patent/TWI433681B/zh not_active IP Right Cessation
- 2009-01-07 CL CL2009000018A patent/CL2009000018A1/es unknown
- 2009-01-07 UY UY031597A patent/UY31597A1/es not_active Application Discontinuation
- 2009-01-07 AR ARP090100036A patent/AR070119A1/es unknown
-
2010
- 2010-06-02 ZA ZA2010/03927A patent/ZA201003927B/en unknown
- 2010-06-22 US US12/820,727 patent/US8633156B2/en not_active Expired - Fee Related
- 2010-06-25 CO CO10076884A patent/CO6290770A2/es not_active Application Discontinuation
- 2010-07-05 MA MA32984A patent/MA31997B1/fr unknown
- 2010-07-06 IL IL206843A patent/IL206843A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI433681B (zh) | 2014-04-11 |
| PE20091305A1 (es) | 2009-09-26 |
| ZA201003927B (en) | 2011-04-28 |
| UY31597A1 (es) | 2009-08-31 |
| TW200942257A (en) | 2009-10-16 |
| CA2711752A1 (en) | 2009-07-16 |
| BRPI0907119A2 (pt) | 2015-07-14 |
| US20110173722A1 (en) | 2011-07-14 |
| PA8811501A1 (es) | 2009-09-17 |
| IL206843A0 (en) | 2010-12-30 |
| CO6290770A2 (es) | 2011-06-20 |
| MA31997B1 (fr) | 2011-01-03 |
| US8633156B2 (en) | 2014-01-21 |
| KR20100111683A (ko) | 2010-10-15 |
| AU2009203810A1 (en) | 2009-07-16 |
| WO2009087082A3 (de) | 2009-09-24 |
| CL2009000018A1 (es) | 2009-06-05 |
| AU2009203810B2 (en) | 2013-07-25 |
| HK1148542A1 (en) | 2011-09-09 |
| EP2229406B1 (de) | 2015-04-22 |
| CN101970476B (zh) | 2014-08-27 |
| JP2011509269A (ja) | 2011-03-24 |
| EP2229406A2 (de) | 2010-09-22 |
| WO2009087082A2 (de) | 2009-07-16 |
| NZ586589A (en) | 2012-04-27 |
| JP5695909B2 (ja) | 2015-04-08 |
| CN101970476A (zh) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
| MY152979A (en) | Novel insulin derivatives having an extremely delayed time-action profile | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| AR077455A1 (es) | Preparaciones insulinicas de accion lenta | |
| CL2011003121A1 (es) | Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso. | |
| HRP20190689T1 (hr) | Muteini suznog lipokalina koji vežu il-4r alfa | |
| PE20130338A1 (es) | Analogos del glucagon | |
| CO6150201A2 (es) | Anticuerpo humanizado contra beta amiloide | |
| PE20120358A1 (es) | Mutantes fgf21 y usos de los mismos | |
| JP2013518115A5 (es) | ||
| RU2011134596A (ru) | Аналоги оксинтомодулина | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| RU2012153753A (ru) | Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов | |
| ME03709B (me) | Fuzijski proteini | |
| NZ630484A (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| RU2012101274A (ru) | Соединения глюкагона, активные в отношении рецептора gip | |
| BR112018000660A2 (pt) | peptídeos anti-inflamatórios e seu uso | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| WO2016105545A3 (en) | Insulin analogues with enhanced stabilized and reduced mitogenicity | |
| PE20200514A1 (es) | Compuestos de mic-1 y usos de estos | |
| MX2012003398A (es) | Agonistas npr-b novedosos. | |
| ES2570937T3 (es) | Un proceso para la preparación de compuestos de insulina | |
| AR075933A1 (es) | Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |